Other News

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Financial by Comments are Disabled

NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024.

Continue Reading →

Imperative Care Announces FDA Clearance and Initial Cases of the Zoom 6F Insert Catheters, the First Insert Catheters Built for Stroke

Neuro by 0 comments

July 17, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom™ 6F Insert Catheters, the company’s latest innovation in elevating stroke care and the first insert catheters developed specifically for ischemic stroke procedures. The company […]

Continue Reading →

At AHRA 2024, Agfa Radiology Solutions highlights intelligent technologies and systems that ensure “One image is all it takes”

Radiology by Comments are Disabled

MORTSEL, Belgium, July 17, 2024 /PRNewswire/ — At the Annual Meeting of AHRA (the Association for Medical Imaging Management), Agfa Radiology Solutions will demonstrate how its solutions help customers address staffing shortages and tight budgets.

Continue Reading

Agfa’s comprehensive portfolio supports “The Next Generation” in medical imaging by using intelligent and innovative technologies to ensure every X-ray image counts. With accurate and high-quality diagnostic information from the first image taken, retakes are reduced: speeding up workflows and enhancing the experience of radiologist, radiographer and patient.

Agfa Radiology Solutions uses intelligent and innovative technologies to ensure every X-ray image in healthcare counts.

Post this

“We understand the challenges our customers are facing in terms of staffing shortages and decreased budgets. Our productivity features and ‘one image is all it takes’ approach empower each X-ray expert to work more efficiently. Additionally, the DR 100 Essential and VALORY™ are designed to be budget-friendly, but still deliver all the essential functions healthcare facilities need – including our renowned MUSICA® image processing software. They demonstrate our commitment to offering solutions that ensure healthcare facilities never need to compromise on image quality, regardless of their staff and budget constraints,” says Bruce Romaglia, Vice President – North America at Agfa Radiology Solutions.
At Agfa’s booth, visitors can discover solutions and special packages that help bring those advantages to every healthcare organization, whatever their budgets.Intelligent technologies for image processing and workflow assistance:
MUSICA®, which comes standard with all Agfa DR and CR systems, automatically analyses the characteristics of raw images and optimizes the processing parameters, independent of body part or dose deviation. Its high image quality and low-dose features have made MUSICA® the “gold standard” in image processing for radiology departments around the world.
The SmartXR® portfolio adds X-ray intelligence to Agfa’s DR solutions, to provide image acquisition support and lighten the radiographer’s workload. Predictive workflow assistance for dose, alignment, patient positioning, image rotation and more help improve operational performance in image acquisition.
About AgfaAgfa develops, produces and distributes an extensive range of imaging systems and workflow solutions for the printing industry, the healthcare sector, as well as for specific hi-tech industries such as printed electronics & renewable energy solutions.The headquarters are located in Belgium. The largest production and research centers are located in Belgium, the United States, Canada, Germany, France, the United Kingdom, Austria, China and Brazil. Agfa is commercially active worldwide through wholly owned sales organizations in more than 40 countries.For more information on Agfa please visit www.agfa.comFollow us at TwitterAgfa, the Agfa rhombus, MUSICA and SmartXR are trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. All rights reserved.All information contained herein is intended for guidance purposes only, and characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. Agfa diligently strives to provide as accurate information as possible, but shall not be responsible for any typographical error.Only the English version of this press release is legally valid. The versions in other languages only represent a translation of the original English version.SOURCE AGFA US Corp.

Continue Reading →

Le Bonheur Children’s and UT Health Science Center Announce Dr. Bret Mettler Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute

Financial by Comments are Disabled

Dr. Mettler comes to Le Bonheur from Johns Hopkins Children’s Center
MEMPHIS, Tenn., July 17, 2024 /PRNewswire/ — Le Bonheur Children’s Hospital has named Bret A. Mettler, MD, its new Chief of Pediatric Cardiac Surgery and Executive Co-Director of the Heart Institute at Le Bonheur and the University of Tennessee Health Science Center. Dr. Mettler will also hold The Susan and Alan Graf Endowed Chair in Pediatric Heart Surgery at Le Bonheur.
He comes to Le Bonheur and UT Health Science Center from Johns Hopkins Children’s Center, where he serves as Director of Pediatric Cardiac Surgery and Co-Director of the Blalock-Taussig-Thomas Pediatric and Congenital Heart Center.
Before his time at Johns Hopkins, Dr. Mettler served as the Director of Cardiac Transplantation and Mechanical Circulatory Support at Vanderbilt University Medical Center in Nashville.
“I am excited for Dr. Mettler to join our talented and dedicated team at Le Bonheur and UT Health Science Center,” said Le Bonheur President Trey Eubanks, MD, FACS. “Bret brings a wealth of knowledge and experience which will allow us to continue our Heart Institute’s mission of providing excellent care for children with complex heart conditions.”
Dr. Mettler specializes in the surgical repair of complex congenital heart disease, heart transplantation and mechanical circulatory support. His research interests include insights into complex congenital heart defects and the development of an artificial pulmonary valve using stem cells.
“Le Bonheur is committed to excellence and providing outstanding care for patients,” said Dr. Mettler. “The Heart Institute has a world-class faculty built by Drs. (Chris) Knott-Craig and (Jeffrey A.) Towbin, and I am pleased to be part of building on that foundation. Le Bonheur really shines for its care for children in an environment built just for them. I am excited about our continued vision for growth and service to the community.”
Le Bonheur Children’s Announces Dr. Brett Mettler, page two of two
Dr. Mettler assumes the chief of Pediatric Cardiac Surgery and executive co-director of the Heart Institute roles from Christopher Knott-Craig, MD, who last year announced he plans to step down as chief and executive co-director of the Heart Institute. Dr. Knott-Craig, along with Dr. Jeffrey A. Towbin, the executive co-director of the Heart Institute and chief of Pediatric Heart Failure and medical director of Cardiomyopathy, Heart Failure and Heart Transplant Services, have been responsible for leading Le Bonheur’s Heart Institute to become a Top 10 program in U.S. News & World Report. They have built the reputation of Le Bonheur’s Heart Institute as an elite surgical and medical program and developed the new 31-bed Cardiovascular Intensive Care Unit. Le Bonheur will honor Knott-Craig and his tenure later this summer.
“I want to thank the medical, surgical and nursing members of the Heart Institute for their very substantial role in helping to recruit Dr. Mettler and for their long-term commitment to excellence and the special care given to their patients,” said Dr. Towbin, who also serves as chief of Cardiology at Le Bonheur and St. Jude Children’s Research Hospital and tenured professor, Department of Pediatrics, Pediatric Cardiology at UT Health Science Center. “I am excited for Le Bonheur’s future and for the innovation that Dr. Mettler brings to Memphis. He is a wonderful addition to our outstanding team.”
Dr. Mettler is a native of South Dakota. He, along with his wife Kelly and their two daughters, will move to Memphis later this year.
About Le Bonheur Children’s Le Bonheur Children’s, based in Memphis, Tenn., provides expert care for children in more than 45 pediatric subspecialties, encompassing robust community programs, a pediatric research institute and regional outpatient centers in Jackson, Tenn., Tupelo, Miss., and Jonesboro, Ark. Le Bonheur also features a 255-bed hospital in Memphis and a 21-bed satellite hospital within Jackson-Madison County General Hospital in Jackson, Tenn. As the primary pediatric teaching affiliate for the University of Tennessee Health Science Center, Le Bonheur trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur has been named a U.S. News & World Report Best Children’s Hospital for 13 consecutive years and is a Magnet-designated facility, the ultimate credential for high-quality patient care and nursing excellence.
For more information, please call (901) 287-6030 or visit lebonheur.org. Connect with us at facebook.com/lebonheurchildrens, x.com/lebonheurchild on Instagram at lebonheurchildrens. 
About University of Tennessee Health Science CenterThe mission of the University of Tennessee Health Science Center is transforming lives through collaborative and inclusive education, research, scholarship, clinical care, and public service. With six colleges – Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing, and Pharmacy – at its main campus in Memphis, in addition to educational and clinical campuses at major hospitals in Memphis, Knoxville, Chattanooga, and Nashville, and sites across the state, UT Health Science Center strives to fulfill its vision: Healthy Tennesseans. Thriving Communities. For more information, visit www.uthsc.edu. You can find the University of Tennessee Health Science Center on Facebook, Instagram, LinkedIn, X, and YouTube.
CONTACT: David Henson(423) 304-9400 [email protected]
Ariss Arena (901) 283-5584 [email protected]
SOURCE Le Bonheur Children’s Hospital

Continue Reading →

AliveCor’s Kardia 12L ECG System Receives Category III CPT Codes

Rhythm by Comments are Disabled

New Codes Establish Path to Reimbursement for First-of-its-Kind Cardiac Technology
MOUNTAIN VIEW, Calif., July 17, 2024 /PRNewswire/ — AliveCor, the global leader in AI-powered cardiology, today announced that the American Medical Association (AMA) has granted new Category III Current Procedural Terminology (CPT) codes that are applicable to the company’s Kardia™ 12L ECG System, which received FDA clearance in June 2024. In accordance with the AMA semi-annual early release schedule, the new codes will be effective January 1st, 2025 and published in the 2025 CPT Code book.
CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. Category III CPT codes allow data collection for new or emerging healthcare approaches and establish a foundation that facilitates reimbursement pathways for healthcare providers.
The following Category III codes for Kardia 12L were accepted by the CPT Editorial Panel meeting for the 2025 CPT production cycle:

0903T Electrocardiogram, Algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report
0904T ECG ALG 12 Algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only
0905T Electrocardiogram, Algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only

“Cardiovascular disease continues to be the leading cause of death in the US, and this recognition from the AMA brings new momentum towards improving access to life-saving cardiac care, including our latest technology,” said Sanjay Voleti, CBO of AliveCor. “Our AI-powered, portable Kardia 12L is AliveCor’s first device developed exclusively for use by healthcare providers, paving the way to bring this clinically-validated ECG technology to patients anytime and anywhere.”
About Kardia 12L ECG and KAI 12L AI Technology
Kardia 12L ECG System combines the power of KAI 12L’s AI technology and the pocket-sized Kardia 12L, to enable faster, easier detection of life-threatening cardiac conditions. KAI 12L is the world’s first AI to detect 35 cardiac determinations, including heart attacks, using a reduced leadset.
Kardia 12L ECG System is battery-operated, weighs just 0.3 pounds – making it significantly smaller, more portable and easier to use than conventional 12-lead ECGs. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler and faster to use than standard 12-lead ECG machines. These features put 12-lead ECG data within reach of more healthcare providers than ever before in a variety of healthcare facilities and acute settings, including primary and urgent care offices, employer clinics, and other under-resourced or rural venues.
For healthcare providers interested in purchasing a Kardia 12L, please visit alivecor.com/products/kardia12L.
About AliveCor
AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With over 250 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.
SOURCE AliveCor, Inc.

Continue Reading →

Bon Secours Mercy Health and Philips sign multi-year strategic collaboration

Financial by Comments are Disabled

July 17, 2024 Patient monitoring platform to deliver tools and time to help patients across 40+ care sites Amsterdam, the Netherlands, and Cincinnati, Ohio – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and Bon Secours Mercy Health (BSMH), one of the nation’s largest Catholic health systems, today announced a multi-year strategic collaboration for patient monitoring. Putting BSMH clinicians in control, the collaboration will reduce the digital burden on staff and give them more time to spend with patients. The partnership provides access to the latest Philips monitoring innovations, including a scalable patient monitoring platform that integrates patient data and provides vital insights. It will standardize patient monitoring for BSMH’s 49 hospitals, reducing costs through a predictable payment model and enabling further reinvestment in innovation. “This collaboration is part of our commitment to drive improved healthcare quality while reducing costs and addressing healthcare issues facing entire communities,” said Jodi Pahl, Chief Nursing Officer for workforce experience and nursing outcomes, Bon Secours Mercy Health. “This 10-year journey will bring innovations that will transform care delivery.” BSMH provides patients care more than 11 million times annually through its network of more than 1,200 care sites, 60,000 associates and 49 hospitals serving communities in Florida, Kentucky, Maryland, New York, Ohio, South Carolina and Virginia, as well as Ireland. “With implementation occurring over the next three years, followed by seven years of maintenance and updates, we’re positioned to be at the leading edge of technology,” said Pahl. “This uplifts our Mission to improve the health and well-being of our communities and supports our commitments to innovation and stewardship.” Julia Strandberg, Chief Business Leader, Connected Care at Philips said: “This partnership is a testament to BSMH’s focus on strong clinical engagement and our combined commitment to improving the patient and staff experience. As BSMH’s clinical technology partner, we’re leaning in to understand their needs and apply innovative technologies that can improve patient outcomes. BSMH is committed to bringing quality care to more people by eliminating time-consuming data roadblocks for their staff.” For further information, please contact: Silvie CasanovaPhilips North America Tel: +1 781 879-0692     Email: silvie.casanova@philips.com Mark GrovesPhilips External RelationsTel: +31 631 639 916Email: mark.groves@philips.com Emma SwannBon Secours Mercy HealthTel: +1 804 837-0413Email: Emma_swann@bshsi.org About Bon Secours Mercy HealthBon Secours Mercy Health (BSMH) is one of the 20 largest health systems in the United States and the fifth-largest Catholic health system in the country. The ministry’s quality, compassionate care is provided by more than 60,000 associates serving communities in Florida, Kentucky, Maryland, New York, Ohio, South Carolina, and Virginia, as well as throughout Ireland. Bon Secours Mercy Health provides care for patients more than 11 million times annually through its network of more than 1,200 care sites, which includes 49 hospitals. In 2023, BSMH provided more than $600 million dollars in community investments across five states, ensuring that cost is not a barrier to health care for our patients in need. In addition to charity care, BSMH invests in programs that address chronic illness, affordable housing, access to healthy food, education and wellness programs, transportation, workforce development and other social determinants of health that directly affect the communities we serve. The Mission of Bon Secours Mercy Health is to extend the compassionate ministry of Jesus by improving the health and well-being of its communities and bring good help to those in need, especially people who are poor, dying and underserved. For more information, visit https://bsmhealth.org/.  About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

Doctor monitoring patient health

Continue Reading →

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Financial by Comments are Disabled

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call.  Starting on July 17th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: https://app.saytechnologies.com/amarin-2024-q2. This Q&A platform will remain open until 24 hours prior to the start of the earnings call. Shareholders can email support@saytechnologies.com for any support inquiries. Conference Call and Webcast Information:  Access to the live call: Go to the investor relations section of the Company’s website at www.amarincorp.com Dial in within the United States: 888-506-0062International dial in: 973-528-0011Access Code: 409616Access to replay: Dial in within the United States: 877-481-4010 International dial in: 919-882-2331  Access Code: 50766A replay of the call will also be available through the Company’s website shortly after the call.  About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.    Availability of Other Information About Amarin  Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.  Amarin Contact Information   Investor & Media Inquiries: Mark Marmur Amarin Corporation plc PR@amarincorp.comInvestor.relations@amarincorp.com

Continue Reading →

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Coronary/Structural Heart by Comments are Disabled

SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035. The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value. Procedures that leverage transseptal delivery include atrial fibrillation ablation, patent foramen ovale (PFO) and atrial septal defect (ASD) repair, percutaneous mitral valve repair, left atrial appendage closure, and percutaneous left ventricular assist device placement, among others. Worldwide revenue from the transseptal access systems market was $941.3 million in 2022, with the global market estimated to expand at a Compound Annual Growth Rate of 7.3%, reaching $2.1 billion by the end of 2033(1). Morph DNA designs enable the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. The DNA name reflects this design, as these tensioning elements appear as a double helix like that in a strand of DNA. This design is intended to enable smooth navigation and prevent “whip,” when the build-up of mechanical forces in the device causes a catheter to suddenly jump from one orientation to another. “All of the biotherapeutic interventions we support for treatment of heart failure, refractory angina, and acute myocardial infarction going forward are expected to utilize this same introducer technology platform,” said Peter Altman, PhD, BioCardia’s President and Chief Executive Officer. “This is an elegant solution to a long-standing technical issue. The solution enhances the level of physician control in our procedures, and BioCardia is working to provide or partner this solution for the roughly five hundred thousand transseptal procedures performed in the United States each year, and for other vascular access markets that can benefit from the advantages our patented solution provides.” About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms. For more information visit: www.BioCardia.com. Forward Looking Statements: This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the Company’s investigational product candidates, the advantages of the Morph DNA design, and the potential transseptal access delivery vascular market for the Morph DNA steerable introducer product Family. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2024, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. (1) Persistence Market Research (2022). “Transseptal Access Systems Market Outlook (2023-2033).” New York, NY. Persistence Market Research Pvt. Ltd.

Continue Reading →
1 … 233 234 235 236 237 … 1,333